Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME

NCT02493725 is registered in ClinicalTrials.gov with Chiba University as lead sponsor.

NCT NCT02493725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME
Lead sponsor
Chiba University
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
October 31, 2016
Enrollment
34 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gullain barre syndrome